Trials / Recruiting
RecruitingNCT05219799
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- University of Missouri-Columbia · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.
Detailed description
Patients with sleep apnea are at increased risk of developing cardiovascular disease - with women at potentially greater risk than men. Contributing mechanisms are not well understood, but may be related to how women respond to low oxygen and, given over 70% of patients with sleep apnea are obese, the impact of obesity. This project seeks to increase our understanding of mechanisms that may contribute to sex differences in the cardiovascular response to low oxygen with the hope that this knowledge will improve the efficacy of current therapies and support the discovery of novel therapeutics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propranolol Hydrochloride | Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures |
| DRUG | Isoproterenol | Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness |
| DRUG | Phentolamine Mesylate | This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min). |
| DRUG | Norepinephrine | Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2022-02-02
- Last updated
- 2025-05-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05219799. Inclusion in this directory is not an endorsement.